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A B S T R A C T
Purpose: In the treatment of epilepsy, the recommendation to add vagus nerve stimulation (VNS) to the
best available drug therapy (BDT) mostly relies on uncontrolled studies which provide limited
information about VNS-speciﬁc beneﬁts. We report ﬁndings from a retrospective matched pairs case–
control study comparing the long-term (>2 years) outcomes of BDT with or without VNS.
Methods: Included were adult patients with therapy-refractory epilepsy who had undergone the pre-
surgical work-up (baseline) and subsequently received BDT with VNS (BDT + VNS) or BDT alone (BDT
group). Patients were matched in pairs for age, gender and follow-up. Health outcomes were assessed at
least 24 months after the baseline by comprehensive postal surveys and included established
psychometric scales.
Results: We obtained data from 20 matched pairs of case and control patients. In both groups, seizures,
health-related quality of life and mood improved over time. More BDT patients experienced a complete
cessation of ‘‘major’’ seizures (12/20 vs. 4/20) whereas, in non-seizure free patients, BDT + VNS patients
showed better seizure frequency reduction (>50% reduction: 12/19 vs. 7/16). BDT + VNS patients
experienced equal drug related and additional VNS related side effects. No clinically relevant effect of
VNS treatment was found on any psychological/psychosocial outcome measure.
Conclusion: This retrospective study provided no positive evidence for therapeutic beneﬁts of adding
VNS to BDT. The follow-up health status of BDT + VNS patients was slightly worse than in patients
receiving BDT alone. Despite minor group differences at baseline the two patient groups who had failed
presurgical evaluation were comparable. Therapeutic improvements during long-term BDT alone are
often underestimated resulting in a misattribution of positive changes to VNS in uncontrolled studies
and reviews. Currently, there is no incontrovertible evidence for the clinical effectiveness of adding VNS
to BDT.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Since its approval as an add-on treatment for drug therapy-
refractory epileptic seizures (Europe: 1994, USA: 1997), vagus
nerve stimulation (VNS) has been widely accepted as the third
approach to the treatment of epilepsy.1–3 As of November 2011,
over 60,000 epilepsy patients had been implanted with a VNS
device and VNS was available in more than 70 countries
(personal communication, Cyberonics Europe Inc.). VNS spear-
headed the concept of (peripheral) neurostimulation for
neurological and neuropsychiatric symptoms.4 However, VNS
is associated with considerable additional costs, risks and
adverse effects. Furthermore, there are speciﬁc restrictions for* Corresponding author. Tel.: +49 228 287 16172; fax: +49 228 287 90 16172.
E-mail address: christian.hoppe@ukb.uni-bonn.de (C. Hoppe).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.11.003the diagnostic application of high-ﬁeld magnetic resonance
imaging (3.0 T+) in patients with implanted or incompletely
removed medical devices. Most critically, about half of the
patients receiving VNS are not expected to experience thera-
peutic beneﬁts in terms of seizure frequency reduction, and no
model for identifying the most suitable patients has been
established thus far.1–3
Given this background, the addition of VNS to best available
drug treatment (BDT) requires unequivocal evidence of the
therapeutic superiority of combined treatment (i.e. BDT + VNS).
Sustained clinical effectiveness of add-on VNS can only be shown
by active-control trials in realistic clinical settings which directly
compare the long-term outcomes of BDT + VNS vs. BDT alone.
Leaving clinical effects at the individual patient level aside, one
must ask for clinically relevant group effects indicating VNS-
speciﬁc therapeutic beneﬁts which more than compensate for the
VNS-speciﬁc costs, risks and adverse effects.vier Ltd. All rights reserved.
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between the widely accepted notion of the therapeutic beneﬁts of
add-on VNS and the lack of compelling supportive evidence from
active-control studies and, more generally, the lack of adequate
studies of VNS for refractory epilepsy.5 Of note, the pre-marketing
double-blind, randomized controlled trials of VNS6–8 and similar
studies9–11 did not address clinical effectiveness, i.e. the therapeu-
tic utility of adding VNS to BDT, but therapeutic efﬁcacy, i.e. the
effects of different stimulation conditions in implanted patients. In
a recent meta-analysis, 69 of 74 identiﬁed studies of VNS for
epilepsy treatment were uncontrolled.1 However, to assign
therapeutic changes in uncontrolled studies to the ‘effects’ of
the treatment given – or even to VNS as a particular part of this
treatment – means making a logical misattribution error. In these
studies, positive changes occurring by chance or through BDT alone
are often underestimated or ignored.12
We are aware of only two studies which evaluated the longer
term (12 months) clinical effects of BDT + VNS as compared to BDT
alone.5,13 Both studies used a prospective active-control study
design and neither study involved randomization or matching of
cases and controls. Sherman et al.5 assessed the seizure and HRQOL
outcome in pediatric patients under BDT with and without add-on
VNS but no VNS-speciﬁc anti-seizure effect was obtained. McGlone
et al.13 assessed HRQOL and memory functions in small samples of
adult epilepsy patients under VNS (i.e. BDT + VNS), ‘‘medical
management’’ (i.e. BDT) or resective surgery, but also found no
beneﬁcial effect of adjunctive VNS as compared to BDT at the one-
year follow-up.
In the present study, we evaluated the therapeutic long-term
(>2 years) effects of adding VNS to BDT in adult epilepsy patients
by employing a retrospective matched pairs case–control study.
We followed therapy-refractory patients after failure of the
presurgical evaluation and hypothesized that patients receiving
VNS in addition to BDT should be better off with regard to seizures,
drug tolerability or health-related quality of life 2 years later. In
addition, we expected the therapeutic beneﬁts obtained through
additional VNS to more than compensate for the costs, risks and
side effects of this treatment.
2. Methods
2.1. Patients
Data recording started in 2006. As the follow-up interval was
intended to be longer than 2 years, the VNS device had to have been
implanted no later than in 2004. From 1998 (when regular
implantations began in our unit) until 2004, 180 adult epilepsy
patients were implanted with the VNS system. In our unit, add-on
VNS is only offered to patients if resective epilepsy surgery has
been excluded as a treatment option or has failed. Therefore, most
of the patients underwent the pre-surgical work-up and were
implanted shortly thereafter. As we were interested in long-term
outcomes, failure of VNS leading to explantation or switching off of
the device was an exclusion criterion for this study. We also
excluded patients who had previously undergone epilepsy surgery.
BDT was deﬁned as the state-of-the-art use and adaptation of
drugs and dosages with no study-related constraints. BDT control
patients were selected from the more than 500 patients who
underwent the comprehensive presurgical work-up between 1997
and 2004, but who did not qualify for epilepsy surgery (and, of
course, were not implanted with VNS). Control patients were
matched for gender, chronological age at the baseline, and the
follow-up interval to VNS patients in a case-wise fashion. Of note,
these matching criteria strongly reduced the number of eligible
patients. No speciﬁc VNS outcome predictors were known at the
time of the study set-up14,15 but the impact of predictive factorswhich were proposed later16,17 was considered during data
analysis.
Patient selection and matching was performed based on the
data from the presurgical evaluation before any recording of
outcome data was initiated. All procedures were consistent with
the Declaration of Helsinki (1991) and the study design was
approved by the local ethical review board (no. 137/06). All
patients included provided written informed consent. No reim-
bursement was paid to the patients for study participation.
2.2. Measures
Clinical data were copied from patient charts to allow further
evaluation of the clinical status at the onset of the treatment
interval under examination. Psychological data and the current
health outcome were assessed via two comprehensive postal
surveys. In the ﬁrst survey, patients completed several newly
deﬁned forms on their current seizure status and antiepileptic drug
(AED) treatment as well as a series of standardized psychometric
questionnaires on HRQOL, mood, personality and health-related
attitudes including the Adverse Events Proﬁle,18 the Quality of Life
Inventory in Epilepsy (10-item form),19 the Subjective Handicap of
Epilepsy questionnaire,20 the Beck Depression Inventory,21 the Self-
Rating Anxiety Scale,22 and the Beﬁndlichkeits-Skalen.23 For reasons
of consistency, patients were asked to answer all items enquiring
about the ‘‘current status’’ in relation to the last four weeks. For the
individual diagnostic evaluation, patients were categorized as
‘‘impaired/salient’’ vs. ‘‘non-impaired/non-salient’’ based on the
published cut-off scores of the respective mood and HRQOL
outcome measures. In addition, attitudes toward seizures and
social support during seizures were recorded (Bonn Psychosocial
Scales on Epilepsy24), and health-related personality measures
(Questionnaire on Locus of Control,25 Tellegen Absorption Scale26)
were applied to evaluate possible mediating effects of psychologi-
cal and psychosocial factors (see the supplementary material for
details of all applied psychometric scales).
In a second survey that was conducted not before two weeks
after receipt of the completed material, patients were asked to
retrospectively complete a subset of similar questionnaires on
mood and HRQOL as experienced during their presurgical
evaluation several years ago (i.e. retrospective baseline). Although
explorative in nature, these retrospective data have at least some
potential to indicate psychological group differences which might
already have existed at the baseline (e.g. higher levels of depression
in one group). Evidently, missing group effects on these measures
does not exclude the possibility of preexisting group differences.
2.3. Data analysis
Baseline data derived from medical charts or retrospective
patient-reports were analyzed separately. As most of the applied
psychometric measures do not provide age-related or other
speciﬁc normative data, the raw scores were used for data
analysis. Mean differences between the matched groups were
tested with non-parametric matched tests (Wilcoxon test, x2-test)
or with student’s T-test for paired samples where appropriate.
Mann–Whitney U-test was used for non-parametric evaluation of
the mean differences between independent groups (e.g. seizure
responder/non-responders). Group differences on the scores
obtained from the psychometric questionnaires were tested by
multivariate unifactorial analyses of variance (MANOVA) with
patient group (BDT + VNS vs. BDT) as the main factor (paired).
Mood and HRQOL changes from baseline to follow-up were tested
with repeated measures MANOVA including ‘‘time of reference’’
(baseline vs. follow-up) as the repeated measures factor. To allow
linear modeling of the effects of group, time and their interaction
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were normalized by using their natural logarithm; this implies
the exclusion of seizure-free patients from all analyses referring
to follow-up data. According to the explorative nature of this
retrospective study, post hoc univariate tests (T-tests for paired
samples) were performed in the absence of signiﬁcant multi-
variate effects and without correcting the signiﬁcance level for
multiple testing. Correlations were calculated as Spearman’s
rank correlation. The level of signiﬁcance was generally set to
a = 0.05 (two-sided), but near-signiﬁcant trends (p < 0.10) are
reported as well. All data entries and statistical analyses were
performed with IBM SPSS Statistics 19 (SPSS Inc.; German
release 19.0.0).
3. Results
We were able to recruit 20 matched pairs of BDT and BDT + VNS
patients. The sociodemographic and clinical characteristics of the
included patients are shown in Table 1. The mean follow-up
interval for both patient groups was 6.8 years (SD 2.1, range: 2–13
years).Table 1
Patient characteristics at baseline.
Matching variables
Age at presurgical work-up 
Sex: male/female 
Follow-up intervald (years) 
Clinical characteristicse
Age at epilepsy onset 
Duration of epilepsy at presurgical work-up 
Etiology: cryptogenic/symptomatic/unclear 
MRI lesion: yes/no 
MRI lesion side: left/right/bilateral 
MRI lesion site: TL/FL/otherf
Pathologies: cortical malformation/hippocampal sclerosis/tumor/trauma/others 
Epilepsy syndrome: focal/multifocal/unclear 
Number of antiepileptic drugs: 1/2/3/4 
Mean number of antiepileptic drugs (SD) 
Seizures and EEGg
Semiology: TLE/FLE/others/unclear 
SPS (yes/no) 
CPS (yes/no) 
SGS (yes/no) 
Mean number of SPS per month 
Mean number of CPS per month 
Mean number of SGS per month 
Mean number of total seizures per month 
EEG, interictal epileptic discharges: left/right/bilateral/noneh,i
EEG, interictal epileptic discharges: FL/TL/FL + TL/central/other/nonei
EEG, ictal epileptic discharges: left/right/bilateral/no event/no correlatej
EEG, ictal epileptic discharges: TL/FL + TL/central region/no event/no correlatej
Retrospective patient-reported seizure baseline data
‘‘Small seizures’’ (per month) 
‘‘Big seizures’’ (per month) 
Total seizures (per month) 
CPS, complex-partial seizures; FL, frontal lobe; SGS, secondarily generalized seizures; S
a x2-test.
b T-test for matched samples.
c Wilcoxon-test.
d Time interval between presurgical work-up to survey.
e Data was copied from patient chart.
f Multiple MRI lesion sites possible.
g Baseline seizure data rely on the medical charts from the presurgical work-up.
h The single seizure-free VNS patient (PSN12) interictally showed infrequent sharp-w
bitemporal theta–delta dysrhythmias (pronounced on the right side).
i Interictal EEG: only epilepsy-speciﬁc elements were considered (e.g. sharp-wave co
j Ictal EEG: refers to the beginning of a (clinical) seizure. Sample sizes: BDT + VNS, n3.1. Case–control matching
Due to pair-wise matching, the patient groups showed no
differences with regard to gender, age at presurgical work-up and
the follow-up interval. Recently, bilateral vs. unilateral interictal
epileptic discharges, cortical malformations vs. other brain
pathologies, and lower vs. higher age at epilepsy onset were
proposed as predictive factors for seizure freedom under VNS
treatment.16,17 The patient groups showed no difference with
regard to these clinical factors.
However, further analysis revealed that the BDT + VNS patients
were more severely affected by epilepsy at the baseline. BDT + VNS
patients showed an increased frequency of multifocal epilepsies
(x2-test, p = 0.02) and complex partial seizures (CPS; Wilcoxon-
test, p = 0.046) and a non-signiﬁcant trend toward increased total
seizures (p = 0.07) as documented in the medical records. In
addition, both groups strongly differed with regard to the mean
baseline number of monthly simple partial seizures (SPS). Of note,
this difference relied on single outliers and therefore did not
become signiﬁcant in a non-parametrical statistical test. Finally,
BDT + VNS patients used more AEDs at the baseline (T-test,
p = 0.005; >2 drugs: BDT + VNS 10/20 vs. BDT 2/20).BDT + VNS (N = 20) BDT (N = 20) p-value
39.8 (10.2) 39.0 (8.5) 0.60b
12/8 12/8 1.00a
6.7 (2.4) 7.0 (1.7) 0.38b
14.1 (8.8) 18.1 (12.2) 0.27b
25.7 (13.4) 21.0 (9.2) 0.22b
7/12/1 5/15/0 0.44a
12/8 16/4 0.17a
7/3/2 8/4/4 0.86a
9/3/1 12/3/1 0.99a
2/5/1/2/2 3/7/1/2/3 1.00a
8/11/1 12/3/5 0.02a
1/9/9/1 6/12/2/0 0.02a
2.50 (0.69) 1.80 (0.62) 0.005b
11/3/2/4 10/1/1/8 0.37a
8/12 7/13 0.74a
18/2 17/3 0.63a
10/10 12/8 0.53a
59.5 (201.6) 2.8 (7.5) 0.22c
7.9 (8.8) 5.0 (8.6) 0.046c
1.0 (2.4) 0.5 (1.2) 0.20c
68.4 (206.3) 8.2 (10.4) 0.07c
4/8/4/2 5/6/3/5 0.62a
1/11/1/1/2/2 1/6/5/2/0/5 0.17a
3/3/3/2/6 4/3/5/1/6 0.93a
7/2/0/2/6 4/2/6/1/6 0.13a
8.2 (8.2) 8.4 (10.1) 0.76c
3.5 (4.6) 4.5 (11.2) 0.41c
11.7 (10.0) 12.9 (13.6) 0.83c
PS, simple partial seizures; TL, temporal lobe.
ave complexes in the right temporal lobe with phase reversal over T4–T2 or T6 and
mplexes). Sample sizes: BDT + VNS, n = 18; BDT, n = 19.
 = 17; BDT, n = 19.
Table 2
Seizure outcome.
BDT + VNS (N = 20) BDT (N = 20) p-value
Self-reported seizure status at follow-up
Seizure free/only auras/seizures 1/0/19 4/0/16 0.15a
‘‘Big seizures’’: seizure free/seizures 4/20 12/20 0.01a
Seizure types: SPS/CPS/GM/drop attack 10/8/8/5 7/10/4/5 >0.16c
Maximum interval of seizure-free days (if not seizure-free) 18.1 (14.0) 19.8 (16.0) 0.71b
Mean number of ‘‘small seizures’’ per month (SD) 4.4 (5.8) 3.6 (3.4) 0.96b
Mean number of ‘‘big seizures’’ per month (SD) 2.8 (4.4) 1.5 (2.6) 0.11b
Total monthly seizure frequency 7.2 (8.4) 5.0 (4.8) 0.59b
Objective change (baseline: medical charts)
Mean %-reduction of ‘‘big seizures’’ (CPS/SGS) [median] 65.0% [80.9%] 59.8% [100.0%] 0.72b
Mean %-reduction of total seizures [median] 39.8% [64.9%] 97.6% [6.8%] 0.052b
Seizure response categorized: worsened (<100%)/unchanged/response
(>50%)/good response (>75%)/seizure free (100%) [%]
2/6/4/7/1 [10/30/20/35/5] 8/5/1/2/4 [40/25/5/10/20] 0.04a
Subjective change (baseline: retrospective patient-report)
Mean %-reduction of ‘‘small seizures’’ [median] 40.7% [50.0%] 54.7% [50.0%] 0.25b
Mean %-reduction of ‘‘big seizures’’ [median] 29.4% [50.0%] 38.3% [80.0%] 0.11b
Mean %-reduction of total seizures [median] 43.8% [47.7%] 53.5% [50.0%] 0.64b
Seizure response categorized: worsened (<100%)/unchanged/response
(>50%)/good response (>75%)/seizure free (100%) [%]
0/10/8/1/1 [0/50/40/5/5] 0/9/6/1/4 [0/45/30/5/20] 0.54a
%-change of maximum interval of seizure-free days (if not seizure-free) [median] 105.6% [50.0%] 160.0% [42.9%] 0.47b
Seizure frequency change ratingd 1.2 (2.4) 1.8 (2.3) 0.31b
Seizure severity change ratingd 1.4 (2.3) 1.0 (2.1) 0.59b
Impact of seizures on. . .e
Bodily well-being 2.1 (1.4) 1.9 (1.4) 0.55b
Bodily performance 2.4 (1.7) 1.8 (1.5) 0.14b
Cognitive performance 2.1 (1.8) 1.8 (1.5) 0.70b
Emotional well-being 2.4 (1.7) 2.9 (1.8) 0.48b
a x2-test.
b Wilcoxon-test.
c Multiple x2-tests on each single seizure type (yes/no).
d Change rating scale from 5 = strongly worsened, to +5 = strongly improved.
e Scale from 0 = no impact, to 5 = strong impact.
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The seizure outcome is presented in Table 2. Regarding the
current seizure status, no signiﬁcant group differences were
obtained in any of the applied measures. Of note, 4/20 BDT patients
as compared to 1/20 BDT + VNS patients reported a complete
release from seizures (duration of seizure freedom: 15–72
months). No differences were shown with regard to the distribu-
tion of self-reported seizure types.Fig. 1. Seizure frequency reduction in non-seizure free patients. To allow repeated
measures ANOVA, the total seizure counts from baseline (medical charts) and
follow-up were normalized by expressing them as natural logarithms (ln); this
excludes seizure-free patients from analysis. Shown are the group mean and the
standard error of the mean of the ln (seizure total count). Effects: group (paired):
F[1,14] = 8.52, p = 0.01; time: F[1,14] = 3.96, p = 0.07; ‘‘group  time’’ interaction:
F[1,14] = 8.21, p = 0.01.The following analyses of seizure change refer to the medical
chart baseline data (for comparison with retrospective subjective
data, see supplementary material). As more BDT patients worsened
or became seizure free and more BDT + VNS showed moderate
seizure improvements over time (>50% and >75% reduction), the
categorized seizure response distribution showed a signiﬁcant
group effect (x2-test, p < 0.04; see Supplementary Fig. 1). Also
with regard to present ‘‘big seizures’’ (current subjective classiﬁ-
cation) and baseline CPS and SGS (medical charts), patients from
both groups experienced signiﬁcant improvements (equal re-
sponder rates of >80%), but more BDT patients reported being free
from these types of seizures (12/20 vs. 4/20 BDT + VNS; x2-test,
p = 0.01). For pairs of non-seizure free patients (n = 15), repeated
measures ANOVA on the total seizure counts (normalized)
revealed a main effect of the group (F[1,14] = 8.52, p = 0.01)
indicating a higher seizure frequency in BDT + VNS patients
irrespective of time; a near-signiﬁcant trend toward a main effect
of time (F[1,14] = 3.96, p = 0.07) indicating seizure reduction across
time in both groups; and a signiﬁcant ‘‘group  time’’ interaction
effect (F[1,14] = 8.21, p = 0.01) indicating better seizure reduction
in non-seizure free BDT + VNS patients as compared to non-seizure
free BDT patients from baseline to follow-up (Fig. 1).
The current AED and VNS treatment as well as the patient-rated
treatment efﬁcacy and tolerability are shown in Table 3. Repeated
measures ANOVA on the number of AEDs showed a main effect of
the paired group factor (F[1,15] = 10.95, p = 0.005), indicating that
BDT + VNS patients used more AEDs than BDT patients irrespective
of time. However, there was no effect on time (p = 0.22) and no
‘‘group  time’’ interaction effect (p = 0.19), indicating no signiﬁ-
cant change in the number of AEDs in the total sample or any of the
two groups over time. However, post hoc group-wise testing
revealed a signiﬁcant increase in the number of AEDs in BDT
Table 3
Treatment evaluation: AED and VNS.
BDT + VNS (N = 20) BDT (N = 20) p-value
Antiepileptic drug treatment
Number of AEDs: (missing data)/1/2/3/4 (1)/2/7/9/1 (3)/0/13/4/0 0.09a
Mean number of AEDs (SD) 2.47 (0.77) 2.24 (0.44) 0.03b
AED side effects: AEP total score 35.8 (8.6) 32.5 (10.6) 0.12b
AED side effects: AEP salient/non-salientc 4/16 4/16 1.00a
AED efﬁcacy rating (1 very good . . . 6 very bad) 3.3 (1.1) 3.0 (1.4) 0.39b
AED tolerability rating (1 very good . . . 6 very bad) 2.5 (1.1) 2.7 (1.5) 0.92b
AED impact on bodily well-being (0 none . . . 5 strong impact) 1.8 (1.6) 2.2 (1.4) 0.23b
AED impact on bodily performance (0 none . . . 5 strong impact) 2.0 (1.5) 2.2 (1.2) 0.68b
AED impact on cognitive performance (0 none . . . 5 strong impact) 2.0 (1.7) 2.3 (1.4) 0.55b
AED impact on emotional well-being (0 none . . . 5 strong impact) 1.9 (1.6) 2.5 (1.4) 0.18b
AED efﬁcacy change since baselined 1.1 (1.9) 1.4 (2.3) 0.38b
AED tolerability change since baselined 0.5 (2.0) 0.3 (1.6) 0.58b
Vagus nerve stimulation
VNS cyclee: standard/rapid 10/10 – –
VNS output current (mA): <0.75/0.75–1.25/>1.25 4/15/1 – –
VNS efﬁcacy rating (1 very good . . . 6 very bad) 3.6 (1.5) – –
VNS tolerability rating (1 very good . . . 6 very bad) 2.1 (1.4) – –
VNS efﬁcacy change since baselined 1.7 (1.6)
VNS tolerability change since baselined 0.5 (1.7)
AED, antiepileptic drugs.
a x2-test.
b Wilcoxon-test.
c AEP cut-off score: >44.
d Change rating scale from 5, strongly worsened, to S + 5, strongly improved.
e VNS cycles: standard (on 30 s, off 300 s, pulse width 500 ms, pulse frequency 50 Hz), rapid (on 7 s, off 30 s, pulse width 250 ms, pulse frequency 25 Hz).
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in non-implanted patients gradually approached the higher baseline
number of AEDs in BDT + VNS patients. In fact, all 6 BDT patients who
were under monotherapy at the baseline currently used at least two
AEDs. Regarding the stability of the AED regimen, 20/40 patients
(50%) did not continue taking any of their baseline AEDs until the
follow-up, 18 patients continued 1 drug, and 2 patients continued 2
drugs, with similar variability in both groups (x2-test, p = 0.81). No
signiﬁcant group effects were obtained for patient-reported
treatment side effects (AEP) and ratings of AED efﬁcacy and
tolerability. Patients rated the efﬁcacy of both treatments, AEDs and
VNS, slightly below ‘‘satisfactory’’ (>3.0) on average. Seizure
responders evaluated AED efﬁcacy similar to non-responders
(Mann–Whitney test, p = 0.35), but experienced better tolerability
(p = 0.013). The number of AEDs at the follow-up was neither
correlated with the patients’ efﬁcacy nor tolerability ratings. The
efﬁcacy and tolerability ratings for VNS from the BDT + VNS patients
were similar to those for AEDs from the total sample. VNS seizure
responders evaluated the efﬁcacy (Mann–Whitney test, p = 0.23)
and tolerability (p = 0.43) of VNS similar to seizure non-responders,
but only 5/12 seizure responders rated VNS efﬁcacy as ‘‘good’’ or
‘‘very good’’. Most VNS patients (18/19) evaluated VNS tolerability as
‘‘satisfactory’’ or better. Of note, in BDT + VNS patients VNS-
associated side-effects added to the unchanged drug-related side
effects. Patient change ratings indicated ‘‘little’’ improvement with
regard to seizures, AED treatment and VNS. Again, no effect of the
treatment group factor was obtained.
3.3. Psychological and psychosocial outcome
Outcomes regarding HRQOL and mood, psychosocial status and
personality are reported in the supplementary material (Supple-
mentary Tables 2–4) as, with two exceptions, no VNS-speciﬁc
group effects were obtained. The categorized SAS score indicated
that more BDT + VNS patients showed an elevated score for anxiety
at the follow-up, in contrast to an equal distribution of the
retrospectively reported anxiety scores at the baseline. Further-
more, BDT + VNS patients showed signiﬁcantly higher satisfaction
with their living conditions at the follow-up.4. Discussion
We report the ﬁndings from a retrospective matched pairs
case–control study on the long-term effects (>2 years) of BDT with
or without add-on VNS in adult patients with therapy-refractory
epilepsies. In the following, we will discuss the clinically relevant
ﬁndings.
4.1. Seizure outcome
As mentioned above, the only study which adequately checked
for the effects of BDT found no evidence for a VNS-speciﬁc anti-
seizure effect, because the non-VNS patients showed quite
comparable clinical improvements.5 Evaluation of the obtained
seizure outcomes in the present study requires careful consider-
ation of the possible selection bias, the obtained seizure freedom
rates, and the seizure response rates in non-seizure free patients.
Due to its retrospective design, this study is biased toward the
treatment. For example, by only including those patients with at
least 24 months of activated VNS, patients experiencing treatment
failure during this period (which approaches 30% in our unit) were
excluded. Thus, the reported seizure outcome of our study
probably overestimates the anticonvulsant effect of VNS. In
addition, we applied an explorative statistical strategy to minimize
the risk of missing existent effects.
Importantly, the seizure outcomes of both groups were in good
accordance to outcomes reported by other groups. Numerous
single-arm studies on add-on VNS found a comparable rate of
seizure-free patients (3–5%) and a comparable rate of seizure
responders (30–50%).1–3,27,28 However, the titles and conclusions
of many of these reports are suggestive for a VNS-speciﬁc
anticonvulsant effect although, for evident logical reasons, changes
occurring over time may never be attributed to the treatment or a
single part of it if no control condition was applied. The
misconception relies on the tacit assumption that the mere
continuation of BDT is unlikely to obtain therapeutic improve-
ments over time. But actually, the outcome of BDT is surprisingly
good and comparable to our own ﬁndings in the BDT sample. For
example, Callaghan et al.12 found an annual rate of seizure
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BDT which cumulated in a seizure remission rate of 33% after 7
years; seizure remission was deﬁned as being seizure-free for at
least 12 months.12 In our study, 12/20 patients (60%) under BDT
reported complete release from ‘‘big’’ seizures at the follow-up as
compared to only 4/20 patients (20%) under BDT + VNS (complete-
ly seizure free: 4/20 vs. 1/20). The seizure remission rate in
BDT + VNS patients, therefore, appears even lower than in BDT
alone which might either indicate that these patients suffer from
more severe epilepsies or that BDT is performed in a less efﬁcient
way for VNS patients (see below).
In contrast, within the subgroup of non-seizure free patients,
BDT + VNS patients reported better improvements of the seizure
frequency. Actually, the obtained ‘group  time’ interaction effect
provides the ﬁrst evidence for VNS-speciﬁc long-term effects on
seizures, namely alignment of BDT + VNS patients to BDT patients
over time. However, this ﬁnding must be interpreted with caution
as the mean %-reduction in the frequencies of ‘‘big’’ seizures was
equal in both groups while the group differences in the baseline
total seizure count and the seizure response seem to partly rely on
the extremely variant frequencies of SPS in both groups. To give an
extreme example, one BDT control patient (#18b) with 1.6 CPS per
month and no SPS at the baseline experienced a complete release
from ‘‘big’’ seizures at the follow-up but as she now reported 12
‘‘small’’ seizures per month her seizure frequency increased by
650%.
4.2. Treatment and adverse effects
The seizure remission rate under BDT + VNS might have been
lower for BDT only patients because medication changes or dosage
adjustments were handled in a more restrictive and ﬁnally less
efﬁcient way in implanted patients. In fact, while BDT + VNS
patients remained on a constantly high number of AEDs a marginal
increase in the number of AEDs was found in BDT patients;
however, the drug load at the follow-up was still higher in
BDT + VNS patients. Some authors suggested that the reduction of
AEDs under VNS is safe but the empirical evidence for this
possibility is inconclusive so far29–31 and this option was not
systematically evaluated in the present study. With regard to the
continuity of the AED regimens over time no group effect was
obtained.
We found an equal burden of AED-related side effects in
patients from both groups at the follow-up. In consequence,
BDT + VNS patients suffer from the typical AED-related and
additional VNS-speciﬁc adverse effects even after more than 2
years of VNS treatment. Our ﬁnding is in line with data from other
groups indicating that patients under BDT + VNS have the highest
subjective complaint scores regarding adverse treatment effects.32
4.3. Psychological and psychosocial outcome
We found a tendency toward general psychological improve-
ments over time for both patient groups, but no compelling
evidence for clinically relevant VNS-speciﬁc effects on HRQOL,
mood or the psychosocial outcome. Although the retrospective
patient reports provided no evidence for group differences at the
baseline, it cannot be totally excluded that the similarity of both
groups at the follow-up actually resulted from a therapeutic
alignment of BDT + VNS patients to BDT patients over time.
Minor treatment effects in favor of BDT + VNS were revealed in
two measures with, however, little or no clinical relevance. Firstly,
more patients under BDT + VNS showed elevated anxiety scores,
but this effect likely represents an artifact resulting from the fact
that the SAS cut-off score equals the mean SAS score of the
BDT + VNS patients. Accordingly, the treatment factor exhibited noeffect on the non-classiﬁed SAS scores. To the best of our
knowledge, increased anxiety has never been reported as a
systematic (and paradoxical) effect of VNS. Secondly, the
BDT + VNS patients showed higher satisfaction with their current
living conditions. Satisfaction with the living conditions (and also
with the professional status) generally increased over time in both
groups (in relation to the retrospective reports), but BDT + VNS
patients reported marginally more improvements. As this concept
is quite broad and likely to depend on many unspeciﬁc external
factors, we are not aware of any speciﬁc mechanism by which VNS
might have caused this improvement.
If no control condition had been implemented the obtained
psychotropic improvements of our BDT + VNS patients could have
easily been misinterpreted as VNS effects. Several single-arm
studies on VNS assessed the short-term outcome (6 months or less)
and reported diverse psychological improvements which, howev-
er, must not be causally attributed to the treatment for logical
reasons.7–9,32–39 Of note, several other open-label studies failed to
ﬁnd compelling evidence for VNS-speciﬁc improvements in
cognitive functioning or emotional well-being.5,6,13,36,40–42 This
‘‘negative’’ evidence and, more generally, the lack of adequately
controlled studies on VNS-speciﬁc psychotropic effects, were not
always taken into account appropriately in more recent
reviews.14,15,43–46
Regarding personality, we found no signiﬁcant effect of the
treatment indicating that VNS did not exhibit speciﬁc effects on
personality. Absorption ability (as an estimate of suggestibility)
was positively correlated with the subjective evaluation of the
seizure response, but beyond this effect no important bias of
personality measures on the outcome evaluation could be
conﬁrmed.
5. Conclusion
At the long-term follow-up, patients under BDT + VNS showed a
slightly worse health status than patients under BDT only as more
BDT patients were free from ‘‘big’’ seizures and BDT + VNS patients
suffered from additional VNS-related side effects. Thus, our study
did not obtain positive evidence for speciﬁc therapeutic beneﬁts of
adding VNS to BDT. The baseline group differences (e.g., seizures,
AEDs) were not large enough to question the relatively high
comparability of patients who all failed the presurgical evaluation.
Future prospective active-control studies should assess VNS effects
in patients matched for seizure and AED status. In particular, there
is no good reason to not ascribe those improvements seen in non-
implanted patients under BDT to the BDT + VNS patients. This,
however, leaves almost nothing over for VNS-speciﬁc improve-
ments. Therapeutic improvements during long-term BDT are often
underestimated resulting in a causal misattribution of positive
changes to VNS in numerous uncontrolled studies and review
papers. VNS is related with high costs, risks, diagnostic constraints,
and adverse effects and the rate of expected treatment failures is
high (about 50%). Currently, no incontrovertible evidence for the
clinical effectiveness of adding VNS to BDT is available.
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